RECORD // Company

vTv Therapeutics Inc.

Built 2026-11-21T11:34:08Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • vTv Therapeutics · Ctgov · exact name match to 'vTv Therapeutics Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001641489-26-000036

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-050001641489-26-0000362026-11-21 11:34 UTCReport an error
Net income (loss)$-11,620,0003 months ended 2026-09-3010-Q2026-11-050001641489-26-0000362026-11-21 11:34 UTCReport an error
Interest expense$09 months ended 2026-09-3010-Q2026-11-050001641489-26-0000362026-11-21 11:34 UTCReport an error
Cash and cash equivalents$77,164,000at 2026-09-3010-Q2026-11-050001641489-26-0000362026-11-21 11:34 UTCReport an error
Contract liabilities, noncurrent$1,830,000at 2026-09-3010-Q2026-11-050001641489-26-0000362026-11-21 11:34 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001641489
Ticker
VTVT
EIN
473916571
CUSIP
918385204
Record ID
sx:sec:0001641489

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 11:34 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 11:34 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 11:34 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 11:34 UTCReport an error
Business address3980 PREMIER DR, SUITE 310, HIGH POINT, NC, 272652026-11-16SEC EDGAR company profile2026-11-21 11:34 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 11:34 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:34 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-26,974,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:34 UTCReport an error
Total assets (at 2025-12-31)$89,899,0002025-12-3110-K, XBRL Assets2026-11-21 11:34 UTCReport an error
Stockholders' equity (at 2025-12-31)$64,437,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:34 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$88,932,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:34 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-25,255,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:34 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2024-12-31)$02024-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:34 UTCReport an error
Operating lease liabilities (at 2024-12-31)$169,0002024-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:34 UTCReport an error
Form D total offering amount (D filed 2024-03-07)$50,961,4572024-03-07D2026-11-21 11:34 UTCReport an error
Form D total amount sold (D filed 2024-03-07)$50,961,4572024-03-07D2026-11-21 11:34 UTCReport an error
Form D industry groupPharmaceuticals2024-03-07D2026-11-21 11:34 UTCReport an error
Form D revenue rangeDecline to Disclose2024-03-07D2026-11-21 11:34 UTCReport an error
Form D date of first sale2024-02-272024-03-07D2026-11-21 11:34 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except…2026-11-05SEC EDGAR 8-K 0001641489-26-000035 (text as filed, excerpt)2026-11-21 11:34 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation or By-Laws (filed 2026-10-06)On October 1, 2026, the Board of Directors of vTv Therapeutics Inc. (the “Company”) approved the adoption of the Company’s Third Amended and Restated By-Laws (the “Amended By-Laws”). The Amended By-Laws were amended and restated, among other things, to: •revise the procedures and requirements for the nomination of directors at meetings of stockholders, including by adding a requirement that a stockholder seeking to nominate one or more directors at a meeting of stockholders deliver to the Company reasonable evidence that such stockholder has complied with the requirements of Rule 14a-19 of the Securities Exchange Act of 1934, as amended, no later than five business days before the meeting…2026-10-06SEC EDGAR 8-K 0001641489-26-000032 (text as filed, excerpt)2026-11-21 11:34 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-06)On August 6, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as…2026-08-06SEC EDGAR 8-K 0001641489-26-000029 (text as filed, excerpt)2026-11-21 11:34 UTCReport an error
Largest institutional holder #1 (13F as filed): SAMSARA BIOCAPITAL, LLC$11,238,3742026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #2 (13F as filed): MILLENNIUM MANAGEMENT LLC$10,160,7562026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #3 (13F as filed): FMR LLC$9,803,7212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #4 (13F as filed): Siren, L.L.C.$6,136,9502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #5 (13F as filed): BAKER BROS. ADVISORS LP$5,584,0222026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$3,556,5322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #7 (13F as filed): Trails Edge Capital Partners, LP$3,207,4792026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #8 (13F as filed): Aisling Capital Management LP$1,882,5002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #9 (13F as filed): MARSHALL WACE, LLP$1,489,4352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$1,223,3922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:34 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.